
    
      Approximately 158 subjects will be enrolled in this study. Each patient will receive 1
      injection and be evaluated for efficacy and safety during a 12 month observation period.
      Randomization will be 1:1. The study is expected to be completed in 24 months, inclusive of
      enrollment and follow-up of all subjects.
    
  